statistiche ricercatore

Continente	#
AS - Asia	320
NA - Nord America	295
EU - Europa	293
SA - Sud America	79
AF - Africa	19
Continente sconosciuto - Info sul continente non disponibili	1
OC - Oceania	1
Totale	1.008

Nazione	#
US - Stati Uniti d'America	283
IT - Italia	155
SG - Singapore	132
BR - Brasile	60
VN - Vietnam	59
CN - Cina	53
DE - Germania	33
AT - Austria	29
FI - Finlandia	16
FR - Francia	11
HK - Hong Kong	11
IN - India	10
IQ - Iraq	8
AR - Argentina	7
PL - Polonia	7
SN - Senegal	6
CZ - Repubblica Ceca	5
GB - Regno Unito	5
ID - Indonesia	5
KR - Corea	5
NL - Olanda	5
TR - Turchia	5
UA - Ucraina	5
BD - Bangladesh	4
CA - Canada	4
CO - Colombia	4
ES - Italia	4
RU - Federazione Russa	4
SE - Svezia	4
ZA - Sudafrica	4
JP - Giappone	3
MA - Marocco	3
PE - Perù	3
AL - Albania	2
CH - Svizzera	2
DZ - Algeria	2
IL - Israele	2
KZ - Kazakistan	2
MX - Messico	2
NP - Nepal	2
PA - Panama	2
PH - Filippine	2
PK - Pakistan	2
PS - Palestinian Territory	2
UZ - Uzbekistan	2
VE - Venezuela	2
AE - Emirati Arabi Uniti	1
AU - Australia	1
AZ - Azerbaigian	1
BG - Bulgaria	1
BY - Bielorussia	1
CL - Cile	1
DO - Repubblica Dominicana	1
EC - Ecuador	1
EE - Estonia	1
EG - Egitto	1
ET - Etiopia	1
GE - Georgia	1
GT - Guatemala	1
HR - Croazia	1
IR - Iran	1
JO - Giordania	1
KE - Kenya	1
KG - Kirghizistan	1
KW - Kuwait	1
LK - Sri Lanka	1
MD - Moldavia	1
MY - Malesia	1
PR - Porto Rico	1
PT - Portogallo	1
QA - Qatar	1
SA - Arabia Saudita	1
SV - El Salvador	1
TN - Tunisia	1
UY - Uruguay	1
XK - ???statistics.table.value.countryCode.XK???	1
Totale	1.008

Nome	#
Bortezomib-loaded mesoporous silica nanoparticles selectively alter metabolism and induce death in multiple myeloma cells	224
ENGINEERED MESOPOROUS SILICA-BASED NANOPARTICLES AS SMART CHEMOTHERAPY FOR BORTEZOMIB ADMINISTRATION	194
A Mesoporous silica-based Nanodevice as a vehicle for Specific Drug Targeting and Improved Efficacy in the treatment of Multiple Myeloma.	139
Foxo3a inhibits tamoxifen-resistant breast cancer progression by inducing integrin α5 expression	127
Mesoporous silica-based nanodevice for targeted cancer therapy	111
FoxO3a Drives the Metabolic Reprogramming in Tamoxifen-Resistant Breast Cancer Cells Restoring Tamoxifen Sensitivity	99
Mesoporous silica-based nanocarrier for targeted cancer therapy	86
Metformin Suppresses Glioblastoma Tumor Growth and Progression Through the AMPK/FoxO3a/Survivin Axis	32
Targeting Class I Histone Deacetylases Triggers Antitumor Responses in Colorectal Cancer In Vitro and In Vivo	20
Totale	1.032

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	33	0	3	3	0	3	1	1	4	0	1	7	10
2022/2023	123	7	9	3	10	15	15	19	17	9	4	10	5
2023/2024	102	9	5	6	2	3	19	10	1	11	3	5	28
2024/2025	249	11	21	9	12	5	17	34	19	39	20	17	45
2025/2026	522	59	24	65	28	86	42	66	47	57	48	0	0
Totale													1.032